0000000000650260

AUTHOR

J Acosta

showing 2 related works from this author

Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the Internati…

2022

Statin intolerance is a clinical syndrome whereby adverse effects (AEs) associated with statin therapy [most commonly statin-associated muscle symptoms (SAMS)] result in the discontinuation of therapy and consequently increase the risk of adverse cardiovascular outcomes. However, complete statin intolerance occurs in only a small minority of treated patients (estimated prevalence of only 3-5%). Many perceived AEs are misattributed (e.g. physical musculoskeletal injury and inflammatory myopathies), and subjective symptoms occur as a result of the fact that patients expect them to do so when taking medicines (the nocebo/drucebo effect)-what might be truth even for over 50% of all patients wit…

KardiologiDrucebo effect Nocebo effect SAMS Statin intoleranceMusclesSAMSNocebo effectLipidsQPRSStatin intolerance.Muscular DiseasesStatin intolerancePhysiology (medical)Drucebo effectHumansOrthopedics and Sports MedicineCardiac and Cardiovascular SystemsHydroxymethylglutaryl-CoA Reductase Inhibitorsdrucebo effect ; nocebo effect ; SAMS ; statin intoleranceJournal of Cachexia Sarcopenia and Muscle
researchProduct

Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study

2021

This international, prospective, cohort study enrolled 20 006 adult (≥18 years) patients from 466 hospitals in 61 countries with 15 cancer types, who had a decision for curative surgery during the COVID-19 pandemic and were followed up until the point of surgery or cessation of follow-up (Aug 31, 2020). Average national Oxford COVID-19 Stringency Index scores were calculated to define the government response to COVID-19 for each patient for the period they awaited surgery, and classified into light restrictions (index 60). The primary outcome was the non-operation rate (defined as the proportion of patients who did not undergo planned surgery). Cox proportional-hazards regression models wer…

MaleCOVID-19 COVIDSURG COVIDSURG CANCEROutcome AssessmentIMPACTSettore MED/18 - CHIRURGIA GENERALEBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Surgery.surgeryCancer surgeryNeoplasms/classificationBIOMEDICINA I ZDRAVSTVO. Javno zdravstvo i zdravstvena zaštita.Surgical oncologyNeoplasmsAcute careCOVID-19 - epidemiologyOutcome Assessment Health CareMedicine and Health Sciences80 and overGlobal healthtimingProspective StudiesUK610 Medicine & healthProspective cohort studyCOVID-19/epidemiologyCOVIDAged 80 and overBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Oncology.BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Kirurgija.Hazard ratioArticlesMiddle AgedOncologyAdult; Aged; Aged 80 and over; Communicable Disease Control; COVID-19; Female; Humans; Male; Middle Aged; Neoplasms; Outcome Assessment Health Care; Proportional Hazards Models; Prospective Studies; SARS-CoV-2; Time-to-Treatment; Withholding Treatment/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemalecancer surgeryCovid-19Life Sciences & BiomedicineMENTAL-HEALTHmental healthCohort studyHumanAdultmedicine.medical_specialtydelay3122 CancersCOVID-19 - prevention and control610 Medicine & healthCOVIDSurg CollaborativeNOTime-to-TreatmentSDG 3 - Good Health and Well-beingLockdownmedicineHumanscancer1112 Oncology and CarcinogenesisOncology & CarcinogenesisElective surgeryLS7_4Proportional Hazards ModelsAgedScience & Technologybusiness.industrySARS-CoV-2Public healthGeneral surgeryBIOMEDICINE AND HEALTHCARE. Public Health and Health Care.COVID-193126 Surgery anesthesiology intensive care radiologyHealth CareCommunicable Disease Control/legislation & jurisprudenceProspective StudieWithholding TreatmentCOVID-19; delay; SARS-CoV-2; surgery; timing; cancer surgery;COVID-19 ; lockdowns ; cancer surgeryCommunicable Disease ControlBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Onkologija.Proportional Hazards ModelNeoplasmbusiness
researchProduct